H. Lundbeck A/S

Company Overview

A multinational pharmaceutical corporation, Lundbeck specializes in creating cutting-edge therapies for brain disorders. Their products have been used to treat millions of people for over 70 years, and the creation and dissemination of their innovative treatments continue to benefit people all over the world. With its headquarters in Denmark, the company has operations in over 50 countries worldwide. Its research centers in the US and Denmark, as well as production facilities in France, Italy, and Denmark. The United States, China, Canada, Spain, Italy, France, Japan, Brazil, Australia, and South Korea are their biggest markets.

Strong sales growth and the introduction of Vyepti in multiple markets, Rexulti with the new indication AADAD, and Abilify Asimtufii were all witnessed by the company in 2023. Every one of them offers an extra chance for development.

Since 2013, Abilify Maintena has been sold as a medication to treat tecton and biporar I disorder in sours. Ability Asimtufi was introduced by Lundbeck in 2023 as a bimonthly intramuscular injection. It was introduced in the United States in partnership with Otsuka Pharmaceutical and is anticipated to receive approval and be introduced in European and international markets starting in 2024 as a maintenance treatment for adult schizophrenia. Abilify Asimtufii will be introduced by Lundbeck, either by itself or in association with Otsuka Pharmaceutical.

Financial Highlights (FY 2024)

Company's Business Segments

• Strategic Brands : Rexulti, Brintellix, Abilify Maintena, Asimtufii, Vyepti, Others.
• Mature Brands : Cipralex, Lexapro, Sabril, Other Pharmaceuticals.